These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 35797760)

  • 1. Survival in smouldering myeloma and symptomatic myeloma: Is there an emerging Will Rogers phenomenon?
    Chakraborty R
    Eur J Cancer; 2022 Sep; 172():234-236. PubMed ID: 35797760
    [No Abstract]   [Full Text] [Related]  

  • 2. Serum markers alone can define high-risk smouldering multiple myeloma: new insights from the Czech Myeloma Group model.
    Sørrig R
    Br J Haematol; 2020 Jul; 190(2):137-138. PubMed ID: 32220013
    [No Abstract]   [Full Text] [Related]  

  • 3. Heterogeneity of enrolment criteria for ongoing smouldering myeloma trials.
    Soomro MA; Hoffman J; Goodman AM; Sborov DW; Mohyuddin GR
    Br J Haematol; 2022 Jun; 197(6):e86-e88. PubMed ID: 35229286
    [No Abstract]   [Full Text] [Related]  

  • 4. The difficult business of assessing new therapies for smouldering multiple myeloma.
    Zonder JA
    Br J Haematol; 2018 Aug; 182(4):463-464. PubMed ID: 29767407
    [No Abstract]   [Full Text] [Related]  

  • 5. Burning questions about smouldering myeloma.
    DeWeerdt S
    Nature; 2020 Nov; 587(7835):S58-S59. PubMed ID: 33239807
    [No Abstract]   [Full Text] [Related]  

  • 6. Applying current smouldering myeloma risk models to a UK single-centre cohort and clinical features at progression.
    Ainley L; Camilleri M; Chavda SJ; McMillan A; Lee L; Popat R; Sillito F; Yong K
    Br J Haematol; 2022 Mar; 196(6):e63-e66. PubMed ID: 34812509
    [No Abstract]   [Full Text] [Related]  

  • 7. Early intervention effective in smouldering multiple myeloma.
    Gourd E
    Lancet Oncol; 2019 Dec; 20(12):e666. PubMed ID: 31679982
    [No Abstract]   [Full Text] [Related]  

  • 8. Early treatment for high-risk smouldering myeloma: has the time come?
    Ludwig H
    Lancet Oncol; 2016 Aug; 17(8):1030-1032. PubMed ID: 27402144
    [No Abstract]   [Full Text] [Related]  

  • 9. Diagnostic performance of
    Hill E; Mena E; Morrison C; Dew A; Choyke P; Lindenberg L; Kazandjian D
    Br J Haematol; 2021 Apr; 193(1):125-128. PubMed ID: 32966607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of
    Garcia JB; Storti P; Iannozzi NT; Marchica V; Agnelli L; Toscani D; Franceschi V; Todaro G; Sammarelli G; Notarfranchi L; Scita M; Palma BD; Raimondi V; Lungu O; Pruneri G; Donofrio G; Giuliani N
    Haematologica; 2024 Feb; 109(2):627-631. PubMed ID: 37608776
    [No Abstract]   [Full Text] [Related]  

  • 11. Smoldering Myeloma and the Art of War.
    Lonial S; Dhodapkar MV; Rajkumar SV
    J Clin Oncol; 2020 Jul; 38(21):2363-2365. PubMed ID: 32463739
    [No Abstract]   [Full Text] [Related]  

  • 12. Regression of smoldering myeloma with treatment of Gaucher disease.
    Barley K; Parekh A; Salam S; Mendu DR; Shukla RP; Vatti D; Verina D; Stauffer C; Salib C; El Jamal S; Teruya-Feldstein J; Duffield AS; Leshchenko VV; Jagannath S; Balwani M; Parekh S
    Blood Adv; 2024 Apr; 8(7):1634-1638. PubMed ID: 38285963
    [No Abstract]   [Full Text] [Related]  

  • 13. The landscape of trials for smoldering multiple myeloma: endpoints, trial design, and lessons learnt.
    Mohyuddin GR; Ouchveridze E; Goodman A; Prasad V
    Leuk Lymphoma; 2021 Nov; 62(11):2793-2795. PubMed ID: 34114943
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of low-dose bortezomib on bone formation in smouldering multiple myeloma.
    Hildebrandt GC; Berno T; Gurule A; Mohan M; Yoon D; Salama M; Zangari M
    Br J Haematol; 2019 Jan; 184(2):308-310. PubMed ID: 29574687
    [No Abstract]   [Full Text] [Related]  

  • 15. Should high risk smoldering myeloma be treated outside a clinical trial: NO.
    Gertz MA; Vaxman I
    Leuk Lymphoma; 2021 Nov; 62(11):2565-2567. PubMed ID: 34261405
    [No Abstract]   [Full Text] [Related]  

  • 16. Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups.
    Boyle EM; Rosenthal A; Ghamlouch H; Wang Y; Farmer P; Rutherford M; Ashby C; Bauer M; Johnson SK; Wardell CP; Wang Y; Hoering A; Schinke C; Thanendrarajan S; Zangari M; Barlogie B; Dhodapkar MV; Davies FE; Morgan GJ; van Rhee F; Walker BA
    Leukemia; 2022 Feb; 36(2):591-595. PubMed ID: 34365473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Smoldering Myeloma: Problems With Study Design as well as Biological and Clinical Implications.
    Biran N; Vesole DH; Donato ML; Ip A; Kaur G; Goldberg S; Siegel DS
    J Clin Oncol; 2020 Apr; 38(12):1367-1368. PubMed ID: 32160077
    [No Abstract]   [Full Text] [Related]  

  • 18. Progress in the Management of Smoldering Multiple Myeloma.
    Schmidt TM; Callander NS
    Curr Hematol Malig Rep; 2021 Apr; 16(2):172-182. PubMed ID: 33983517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Smoldering Myeloma Presenting with Renal Histopathology of Monoclonal Gammopathy of Renal Significance: Adding to the Complexity.
    Kousios A; Duncan N; Charif R; Roufosse C
    J Am Soc Nephrol; 2018 Dec; 29(12):2901. PubMed ID: 30377233
    [No Abstract]   [Full Text] [Related]  

  • 20. Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma.
    Dalla Palma B; Marchica V; Pedrazzoni M; Accardi F; Notarfranchi L; Goldoni M; De Luca F; Costa F; Storti P; Toscani D; Sammarelli G; Bonomini S; Aversa F; Giuliani N
    Br J Haematol; 2018 Dec; 183(5):812-815. PubMed ID: 29143308
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.